Horizon Scanning Centre May Brodalumab for moderate to severe plaque psoriasis SUMMARY NIHR HSC ID: 5524
|
|
- Wesley Rose
- 5 years ago
- Views:
Transcription
1 Horizon Scanning Centre May 2014 Brodalumab for moderate to severe plaque psoriasis SUMMARY NIHR HSC ID: 5524 This briefing is based on information available at the time of research and a limited literature search. It is not intended to be a definitive statement on the safety, efficacy or effectiveness of the health technology covered and should not be used for commercial purposes or commissioning without additional information. Brodalumab is intended to be used for the treatment of moderate to severe plaque psoriasis in patients who have failed to respond to, have a contraindication to, or are intolerant to at least one systemic therapy. If licensed, it would offer an additional treatment option for patients who may not have responded to topical or systemic therapies, and offer an alternative to treatments with other biological agents. Brodalumab is a monoclonal antibody that targets and blocks the signalling pathway of interleukin receptors (IL-17A, IL-17F and IL-23). Brodalumab does not have Marketing Authorisation in the EU for any indication. Plaque psoriasis is the most common type of psoriasis, representing 90% of cases. The estimated UK prevalence of psoriasis is %, with 1.1% suffering with severe disease. It has a bimodal onset, with the first peak occurring in persons aged 16 to 22 years, and the second in persons aged 57 to 60 years. The prevalence of psoriasis in those younger than 10 years is estimated to be 0.55% and 1.4% in those aged between 10 and 19 years. The estimated prevalence of people currently eligible for biological therapy in England is 1.1% of those with psoriasis, equating to 7,100 people. Chronic plaque psoriasis is typified by itchy, well demarcated circular-to-oval bright red/pink elevated lesions (plaques) with overlying white or silvery scale, distributed symmetrically over extensor body surfaces and the scalp. Patients with psoriasis commonly experience a reduced overall quality of life and the adverse psychosocial issues associated with the condition can further worsen outcomes for patients with psoriasis. Current treatment options include topical ointments and emollients, phototherapy, systemic therapies (e.g. oral retinoids) and biological therapies. Brodalumab is currently in phase III clinical trials comparing its effect on the severity and extent of psoriasis against treatment with ustekinumab and placebo. This trial is expected to complete in This briefing presents independent research funded by the National Institute for Health Research (NIHR). The views expressed are those of the author and not necessarily those of the NHS, the NIHR or the Department of Health., University of Birmingham nihrhsc@contacts.bham.ac.uk Web:
2 TARGET GROUP Psoriasis: plaque form; moderate to severe patients who have failed to respond to, have a contraindication to, or are intolerant to at least one systemic therapy. TECHNOLOGY DESCRIPTION Brodalumab (AMG 827, KHK 4827) is a monoclonal antibody which targets the interleukin (IL) 17 receptor, blocking the signalling pathway of IL-17A, IL-17F and IL-25. Brodalumab is intended for the treatment of moderate to severe plaque psoriasis as an alternative to other biological agents, in patients who have not responded to, have a contraindication to, or are intolerant to at least one systemic therapy. Brodalumab is administered subcutaneously (SC), at a dose of 140mg or 210mg on day 1 of weeks 1 and 2, and then every other week. Brodalumab does not currently have Marketing Authorisation in the EU for any indication. Brodalumab is currently in phase III trial development for plaque psoriasis and psoriatic arthritis. It is also undergoing phase II trials for asthma. INNOVATION and/or ADVANTAGES If licensed, brodalumab will offer an additional treatment option for patients with plaque psoriasis who have not have responded to topical or systemic therapies, and offer an alternative to other biological agents. DEVELOPER Amgen. AVAILABILITY, LAUNCH OR MARKETING In phase III clinical trials. PATIENT GROUP BACKGROUND Psoriasis is an inflammatory skin condition typified by red, scaly lesions of the skin 1 which occur as a result of a rapid turnover of skin cells 2. The cause of psoriasis is not known; however genetics, the environment and an overactive immune system (in particular, T cells) are thought to play a part 3. Psoriasis typically follows a relapsing and remitting course, with flare ups occurring spontaneously 4. Contributors to flare ups include stress, infections, medications, sunlight, trauma, hormonal changes, smoking and alcohol 2. Plaque psoriasis is characterised by well-defined, sharply demarcated, erythematous plaques, which can be one centimetre to several centimetres in size. Plaques appear as dry, thin, silvery-white scales, and often smaller plaques merge forming larger plaques, particularly over the leg and trunk areas. Plaques may form across specific areas such as 2
3 the scalp, trunk, limbs, buttocks, elbows and knees, but can also manifest across the entire body causing pain and pruritus 5. Other forms of psoriasis include pustular psoriasis, nail psoriasis, guttate psoriasis and erythrodermic psoriasis 2. Patients with psoriasis often experience feelings of self-consciousness and embarrassment, and as a result, may suffer unemployment, social isolation and depression; all factors which contribute to a reduction in overall patient quality of life 6. The adverse psychosocial issues associated with the condition also contribute to worsening outcomes for patients with psoriasis a. NHS or GOVERNMENT PRIORITY AREA NHS England NHS Standard Contract for Specialised Dermatology Services (All ages). A12/S/a. CLINICAL NEED and BURDEN OF DISEASE Plaque psoriasis is the most common form of psoriasis representing approximately 80% to 90% of cases 1. The estimated UK prevalence of psoriasis is % 7,4, with 1.1% of people suffering severe disease 8. It has a bimodal onset, with the first peak occurring in persons aged 16 to 22 years, and the second in persons aged 57 to 60 years. The prevalence of psoriasis in those younger than 10 years is estimated to be 0.55%, and it is 1.4% of those aged between 10 and 19 years 7,9. Approximately 1 in 50 people will develop psoriasis at some stage 2. The estimated prevalence of people currently eligible for biological therapy in England is 1.1% of those with psoriasis, equating to 7,100 people 8. Females typically develop plaque psoriasis earlier than males, and patients with a positive family history for psoriasis also tend to have an earlier age of onset 7. Acute flares or relapses of plaque psoriasis may evolve into more severe disease, such as pustular or erythrodermic psoriasis 5. Psoriasis is also associated with a number of co-morbidities including psoriatic arthritis and cardiovascular disease a. The significant reduction in quality of life and psychosocial disability suffered by people with psoriasis underlies the need for prompt, effective treatment, and long-term disease control 10. In , there were 12,735 admissions for psoriasis (ICD-10 L40) in England, resulting in 16,016 bed-days and 13,315 finished consultant episodes 11. Thirty-one deaths from psoriasis were registered in England and Wales during 2012 (ICD-10 L40) 12. PATIENT PATHWAY RELEVANT GUIDANCE NICE Guidance NICE technology appraisal in development. Psoriasis (plaque, moderate to severe) - secukinumab [ID718]. Expected July NICE technology appraisal. Ustekinumab for the treatment of adults with moderate to severe psoriasis (TA180). September NICE technology appraisal. Adalimumab for the treatment of adults with psoriasis (TA146). June a Expert personal opinion. 3
4 NICE technology appraisal. Infliximab for the treatment of adults with psoriasis (TA134). January NICE technology appraisal. Etanercept and efalizumab for the treatment of adults with psoriasis (TA103). July NICE clinical guideline. Psoriasis: The assessment and management of psoriasis (CG153). October NICE quality standard. Psoriasis (QS40). August NICE interventional procedure guidance. Grenz rays therapy for inflammatory skin conditions (IPG236). November Other Guidance NHS Clinical Knowledge Summary. Psoriasis Scottish Intercollegiate Guidelines Network. Diagnosis and management of psoriasis and psoriatic arthritis in adults (121) CURRENT TREATMENT OPTIONS Treatment options for psoriasis aim to reduce symptoms and improve patient quality of life. Topical treatments are usually offered as first line therapy, followed by phototherapy and/or systemic therapies as second line treatment, and biological therapies as third line treatment regimes. The majority of psoriasis cases are managed at the primary care level, though up to 60% of patients may require referral to a specialist 15. Current treatment options for plaque psoriasis include 16,17,18,19,20 : Topical (alone or in combination) Emollients. Corticosteroids: betamethasone dipropionate. Vitamin D analogues: calcipotriol, calcitriol, tacalcitol and tazarotene (with or without phototherapy). Tars (with or without phototherapy). Dithranol (with or without phototherapy). Retinoids: tazarotene. Salicyclic acid. Tacrolimus ointment (not licensed for this indication). Phototherapy Broad- or narrow-band UVB and psoralen and UVA combination (PUVA). Systemic therapies (for the treatment of patients with severe or refractory psoriasis) Oral retinoids: acitretin (with or without phototherapy). Hydroxycarbamide (not licensed for this indication). Ciclosporin. Methotrexate. Biological therapies (for the treatment of patients intolerant, contraindicated or refractory to other treatments) Drugs affecting the immune response: Adalimumab (TNF-α inhibitor). 4
5 Etanercept (TNF inhibitor). Infliximab (TNF-α inhibitor). Ustekinumab (IL-12 and IL-23 inhibitor). EFFICACY and SAFETY Trial NCT , , EUCTR ; brodalumab vs placebo; phase II. NCT , , EUCTR ; brodalumab; phase II extension. Sponsor Amgen. Amgen. Status Complete and published. Ongoing. Source of Publication 21,22, trial registry 23. Abstract 24, trial registry 25 information Location EU (not UK), USA, Canada and Australia. EU (not UK), USA, Canada and Australia. Design Randomised, placebo-controlled. Non-randomised. Participants n=198; aged 18 to 70 years; moderate to severe plaque psoriasis for at least 6 months; at least one previous phototherapy or systemic psoriasis therapy; affected BSA b 10% and PASI c 12 at screening and baseline. n=181; aged 18 and over; completed 16 week evaluation in study NCT without any serious adverse event or without any adverse event which could be detrimental to the subject if treatment continued. Schedule Follow-up Primary outcome/s Secondary outcome/s Key results Randomised to brodalumab, 70mg, 140mg or 210mg, SC on day 1 and weeks 1, 2, 4, 6, 8 and 10 or 280mg every 4 weeks (placebo on weeks 1, 2 and 6): or matching placebo, SC. Patients receive brodalumab 210mg or 140mg, SC on day 1, weeks 1 and 2 and then every two weeks. Active treatment period 10 weeks. Followup 16 to 22 weeks. Active treatment period and follow-up period up to 360 weeks. % improvement in PASI score. AEs; change in laboratory parameters and vital signs. Proportion of subjects with % PASI score Proportion of subjects with spga of 0 or improvements of 75, 50, 90 and 100; 1; percentage improvement in PASI BSA involvement; short-term safety score; proportion of subjects with % profile; pharmacokinetics; spga d of 0 or improvement in PASI score of 50, 75, and 100; BSA involvement. For brodalumab: 70mg (n=39), 140mg (n=39), 210mg (n=40), 280mg (n=42) and placebo (n=38), respectively (p values vs placebo unless specified otherwise): mean % improvement in PASI, 45.0%, 85.9%, 86.3%, 76.0% and 16.0% (all p<0.001); clinical response seen within 2 weeks and PASI improvement similar in patients regardless of prior biological therapy; %patients with 50%, 75%, 90% or 100% PASI score improvement, significantly higher in brodalumab groups vs placebo; mean improvement from baseline in BSA points, 9.5, 21.1, 22.1, 16.1 and 0.9 (all p<0.001 except 70mg brodalumab, p<0.01); mean % area All patients received brodalumab 210mg every 2 weeks (patients weighing <100kg given 140mg every 2 weeks). spga=0, 63% (n=175, 95% CI 55, 70) at week 12, 62% (95% CI 54, 70) at week 48 and 52% (95% CI 44, 60) at week 96; spga=0 or 1, 90% (n=175, 95% CI 85, 94) at week 12, 85% (95% CI 79, 90) at week 48 and 76% (95% CI 68, 82) at week 96. b Body surface area. c Psoriasis area and severity index. d Static physician s global assessment. 5
6 Adverse effects (AEs) Expected reporting date affected, 14.8, 3.8, 3.0, 5.2 and 22.5 (all p<0.001 except 70mg brodalumab, p<0.01); improvements in skin biomarkers in brodalumab group, not significantly different from placebo (sample of biopsies, n=20); DLQI e score, 6.5, 2.0, 2.0, 3.9 and 10.3 (p<0.05); SF- 36 f physical component, 51.9, 54.8, 52.1, 52.5 and 50.1; SF-36 mental component, 47.8, 51.9, 53.8, 50.9 and 46.9; %patients with spga clear or minimal disease, 26%, 85%, 80%, 69% and 3% (all p<0.001, except 70mg brodalumab, p<0.01). Total number of AEs per group, placebo, 23 (62%), 70mg, 26 (68%), 140mg, 27 (69%), 210mg, 33 (82%), 280mg, 30 (73%); serious AEs, 1 in both 70mg and 210mg brodalumab groups and 1 in placebo group. Brodalumab was discontinued in 3 (2%) patients. Common (at least 4 patients) AEs included: nasopharyngitis, upper respiratory tract infection, arthralgia, injection-site erythema, pain in extremity and nausea. - December % reported AEs by week 96. Most common AEs ( 10% of subjects), nasopharyngitis (25%), upper respiratory tract infection (18%) and arthralgia (13%). AEs grade 3 reported in 12.2% of subjects. Serious AEs reported in 6.6% of subjects, and included acute cholecystitis, constipation, pyelonephritis, oesophageal adenocarcinoma, fatal aortic aneurysm rupture and benign parathyroid tumour. Trial NCT , , EUCTR , AMAGINE-2; brodalumab vs. ustekinumab vs. placebo; phase III. NCT , , EUCTR , AMAGINE-3; brodalumab vs. ustekinumab vs. placebo; phase III. NCT , , EUCTR , , AMAGINE-1; brodalumab vs. placebo; phase III. Sponsor Amgen. Amgen. Amgen. Status Ongoing. Ongoing. Ongoing. Source of information Trial registry 26. Trial registry 27. Trial registry 28, press release 29. Location EU (not UK), USA, Canada and Australia. EU (not UK), USA, Canada, Australia and the EU (not UK), USA, Canada and Switzerland. Russian Federation. Design Randomised, active and placebo-controlled. Randomised, active and placebo-controlled. Randomised, placebocontrolled. Participants n=1,800 (planned); aged 18-75; moderate to severe plaque psoriasis for at least 6 months with BSA 10%, PASI 12 and spga 3 at screening and baseline. n=1,881 (planned); aged 18-75; moderate to severe plaque psoriasis with BSA 10%, PASI 12 and spga 3 at screening and baseline. n=661 (planned); aged 18-75; moderate to severe plaque psoriasis for at least 6 months with BSA 10%, PASI 12 and spga 3 at screening and baseline. e The Dermatology Life Quality Index. f 36-Item Short-Form Health Survey. 6
7 Schedule Randomised to: Arm 1 brodalumab 210mg or 140mg, SC on day 1, weeks 1 and 2, and every 2 weeks until week 12, when subjects rerandomised to receive brodalumab 210mg every 2 weeks or 140mg every 2, 4 or 8 weeks. Arm 2 ustekinumab 45mg or 90mg, SC on day 1 and weeks 4, 16, 28 and 40. At week 52, subjects switch to brodalumab 210mg every 2 weeks. Randomised to: Arm 1 brodalumab 210mg or 140mg, SC on day 1, weeks 1 and 2, and every 2 weeks until week 12, when subjects rerandomised to receive brodalumab 210mg every 2 weeks or 140mg every 2, 4 or 8 weeks. Arm 2 ustekinumab 45mg or 90mg, SC on day 1 and weeks 4, 16, 28 and 40. At week 52, subjects switch to brodalumab 210mg every 2 weeks. Randomised to brodalumab 210mg or 140mg, all SC and given on day 1, weeks 1, 2, and then every 2 weeks until week 12, subjects then rerandomised to continue treatment or receive placebo SC; or placebo SC until week 12 and then assigned to receive 210mg brodalumab. Follow-up Arm 3 placebo, SC on day 1, weeks 1 and 2, and every 2 weeks until week 12, when subjects assigned to brodalumab 210mg every 2 weeks. Induction period 12 weeks, maintenance 40 weeks and long-term extension period up to 5 years. Follow-up 5 years. Improvement in PASI; spga score. Patient reported outcomes symptom score; AEs; presence of antibrodalumab antibodies. Arm 3 placebo, SC on day 1, weeks 1 and 2, and every 2 weeks until week 12, when subjects assigned to brodalumab 210mg every 2 weeks. Induction period 12 weeks, maintenance 40 weeks and long-term extension period up to 5 years. Follow-up 5 years. Improvement in PASI; spga score. Patient reported outcomes symptom score; AEs; presence of antibrodalumab antibodies. Follow-up period 5 years and 3 months. Primary outcome/s Improvement in PASI; spga score. Secondary Patient reported outcomes outcome/s symptom score; AEs; presence of antibrodalumab antibodies. Key results - - PASI response for 210mg brodalumab, 140mg brodalumab vs placebo, respectively: PASI 75 response, 83.3%, 60.3% vs 2.7%; PASI 90 response, 70.3%, 42.5% vs 0.9%; PASI 100 response, 41.9%, 23.3% vs 0.5%. Adverse effects (AEs) Expected reporting date - - Most common AEs (>5% of participants), nasopharyngitis, upper respiratory tract infection and headache; serious AEs, 1.8% in 210mg group, 2.7% in 140mg group and 1.4% in placebo group. Q Q Q
8 ESTIMATED COST and IMPACT COST The cost of brodalumab is not yet known. The costs of other biological therapies for psoriasis are detailed below 30. Drug Dose Unit cost Annual cost Adalimumab Initially 80mg SC, then 352 (40mg, prefilled 9,504 (Humira) 40mg on alternate weeks, one week after initial dose. syringe). Etanercept 25mg SC twice weekly 89 (25mg, prefilled 9,256 (Enbrel) Infliximab (Remicade) Ustekinumab (Stelara) or 50mg once weekly. 50mg/kg intravenously repeated 2 weeks and 6 weeks after initial dose and then every 8 weeks. Initially 45mg SC, then 45mg 4 weeks after initial dose, then 45mg every 12 weeks. syringe). 420 (100mg, vial). 11,760 g 2147 (45mg, prefilled syringe). 12,882 IMPACT - SPECULATIVE Impact on Patients and Carers Reduced mortality/increased length of survival Other: improved quality of life and wider societal benefits (e.g. earlier return to normal activities, including employment). Reduced symptoms or disability No impact identified Impact on Health and Social Care Services Increased use of existing services Re-organisation of existing services Other: Decreased use of existing services Need for new services None identified Impact on Costs and Other Resource Use Increased drug treatment costs Other increase in costs: Other: uncertain unit cost compared to existing treatments Other Issues Clinical uncertainty or other research question identified: Reduced drug treatment costs Other reduction in costs: specify, None identified None identified g Average adult bodyweight (Health Survey for England (HSE) 2010): adults 77.9kg. 8
9 REFERENCES 1 American Academy of Dermatology working group. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. Journal of the American Academy of Dermatology 2011;65: Patient.co.uk. Psoriasis. November Accessed 8 May Psoriasis Association. March Accessed 8 May National Institute for Health and Care Excellence. The assessment and management of psoriasis. Clinical Guideline CG153. Manchester: NICE; October American Academy of Dermatology working group. Guidelines for the management of psoriasis and psoriatic arthritis. Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. Journal of the American Academy of Dermatology 2008;58: Armstrong AW, Schupp C, Wu J, et al. Quality of life and work productivity impairment among psoriasis patients: findings from the national psoriasis foundation survey data PLOS ONE 2012;7(12):e Gefland JM, Weinstein R, Porter SB, et al. Prevalence and treatment of psoriasis in the United Kingdom: a population-based study. Archives of Dermatology 2005;141(12): National Institute for Health and Care Excellence. Costing statement: Ustekinumab for the treatment of adults with moderate to severe psoriasis. London: NICE; September Chaplin S and Atherton D. Etanercept: a new option in paediatric plaque psoriasis. Future Prescriber 2009;9(3): Tofacitinib for moderate to severe chronic plaque psoriasis second line. University of Birmingham, November Health and Social Care Information Centre. Hospital episode statistics for England. Admitted patient care, Office for National Statistics. Mortality statistics: deaths registered in England and Wales (Series DR) Table NHS Clinical Knowledge Summary. Psoriasis. December Accessed 7 May Scottish Intercollegiate Guidelines Network. Diagnosis and management of psoriasis and psoriatic arthritis in adults. National clinical guideline 121. Edinburgh: SIGN; October National Institute for Health and Care Excellence. The assessment and management of psoriasis. Clinical guideline CG153. Manchester: NICE; October Dimethyl fumarate for plaque psoriasis. University of Birmingham, November Hsu S, Papp KA, Lebwohl MG et al. Consensus guidelines for the management of plaque psoriasis. Archives of Dermatology. 2012;148(1): Smith CH, Anstey AV, Barker JN et al. British Association of Dermatologists' guidelines for biologic interventions for psoriasis British Journal of Dermatology 2009;161(5): National Institute for Health and Care Excellence. Psoriasis: final scope. London: NICE; December British Medical Association and Royal Pharmaceutical Society of Great Britain. British National Formulary. BNF 63. London: BMJ Group and RPS Publishing, March Gordon KB, Kimball AB, Chau D et al. Impact of brodalumab treatment on psoriasis symptoms and health-related quality of life: use of a novel patient-reported outcome measure, the Psoriasis Symptom Inventory. British Journal of Dermatology 2014;170: Papp KA, Leonardi C, Menter A et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. The New England Journal of Medicine 2012;366(13): ClinicalTrials.gov. Study to evaluate the safety, tolerability, and efficacy of AMG 827 in subjects with psoriasis. Accessed 30 April Papp K, Menter A, Milmont C et al. Maintenance of clinical response with long-term brodalumab (AMG 827) therapy for psoriasis: week 96 results from an open-label extension study. Journal of the American Academy of Dermatology 2014;70(5):Supplement 1, page AB174. 9
10 25 ClinicalTrials.gov. Study to assess the long-term safety, tolerability, and efficacy of AMG 827 in subjects with psoriasis. Accessed 30 April ClinicalTrials.gov. Study of efficacy and safety of brodalumab compared with placebo and ustekinumab in moderate to severe plaque psoriasis subjects (AMAGINE-2). Accessed 30 April ClinicalTrials.gov. Study of efficacy and safety of brodalumab compared with placebo and ustekinumab in moderate to severe plaque psoriasis subjects (AMAGINE-3). Accessed 30 April ClinicalTrials.gov. Study of efficacy, safety, and withdrawal and retreatment with brodalumab in moderate to severe plaque psoriasis subjects (AMAGINE-1). Accessed 30 April FierceBiotech. Amgen and AstraZeneca announce positive results from phase 3 study of brodalumab (AMG 827) in patients with moderate-to-severe plaque psoriasis. 9 May British Medical Association and Royal Pharmaceutical Society of Great Britain. British National Formulary. BNF 67. London: BMJ Group, RCPCH Publications, Ltd and the Royal Pharmaceutical Society of Great Britain,
Horizon Scanning Centre March Tildrakizumab for moderate to severe plaque psoriasis SUMMARY NIHR HSC ID: 6798
Horizon Scanning Centre March 2015 Tildrakizumab for moderate to severe plaque psoriasis SUMMARY NIHR HSC ID: 6798 This briefing is based on information available at the time of research and a limited
More informationHorizon Scanning Centre March Ixekizumab for moderate to severe chronic plaque psoriasis SUMMARY NIHR HSC ID: 5209
Horizon Scanning Centre March 2015 Ixekizumab for moderate to severe chronic plaque psoriasis SUMMARY NIHR HSC ID: 5209 This briefing is based on information available at the time of research and a limited
More informationHorizon Scanning Centre January Apremilast for psoriasis SUMMARY NIHR HSC ID: 2652
Horizon Scanning Centre January 2013 Apremilast for psoriasis SUMMARY NIHR HSC ID: 2652 This briefing is based on information available at the time of research and a limited literature search. It is not
More informationUstekinumab (Stelara) for psoriatic arthritis second line after disease modifying anti rheumatic drugs (DMARDs)
Ustekinumab (Stelara) for psoriatic arthritis second line after disease modifying anti rheumatic drugs (DMARDs) January 2010 This technology summary is based on information available at the time of research
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Proposed Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Proposed Health Technology Appraisal Dimethyl fumarate for treating moderate to severe Draft scope (pre-referral) Draft remit/appraisal objective To appraise
More informationHorizon Scanning Centre November Secukinumab for active and progressive psoriatic arthritis. SUMMARY NIHR HSC ID: 5330
Horizon Scanning Centre November 2012 Secukinumab for active and progressive psoriatic arthritis. SUMMARY NIHR HSC ID: 5330 Secukinumab is a high-affinity fully human monoclonal antibody that antagonises
More informationCertolizumab pegol (Cimzia) for psoriatic arthritis second line
Certolizumab pegol (Cimzia) for psoriatic arthritis second line This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationRisankizumab (by subcutaneous injection) for moderate to severe chronic plaque psoriasis
NIHR Innovation Observatory Evidence Briefing: November 2017 Risankizumab (by subcutaneous injection) for moderate to severe chronic plaque psoriasis NIHRIO (HSRIC) ID: 9708 NICE ID: 9191 LAY SUMMARY Plaque
More informationCertolizumab pegol (Cimzia) for chronic plaque psoriasis in adults
NIHR Innovation Observatory Evidence Briefing: April 2017 Certolizumab pegol (Cimzia) for chronic plaque psoriasis in adults NIHRIO (HSRIC) ID: 2406 NICE ID: 9112 LAY SUMMARY Plaque psoriasis is the most
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Psoriasis: the management of psoriasis 1.1 Short title Psoriasis 2 The remit The Department of Health has asked NICE: 'to produce
More informationHorizon Scanning Centre March Denosumab for glucocorticoidinduced SUMMARY NIHR HSC ID: 6329
Horizon Scanning Centre March 2014 Denosumab for glucocorticoidinduced osteoporosis SUMMARY NIHR HSC ID: 6329 This briefing is based on information available at the time of research and a limited literature
More informationScottish Medicines Consortium
Scottish Medicines Consortium ustekinumab, 45mg solution for injection (Stelara ) No. (572/09) Janssen-Cilag Ltd 15 January 2010 The Scottish Medicines Consortium (SMC) has completed its assessment of
More informationHorizon Scanning Centre November Faldaprevir with BI for chronic hepatitis C infection, genotype 1 SUMMARY NIHR HSC ID: 7688
Horizon Scanning Centre November 2012 Faldaprevir with BI 207127 for chronic hepatitis C infection, genotype 1 SUMMARY NIHR HSC ID: 7688 This briefing is based on information available at the time of research
More informationSingle Technology Appraisal (STA) Tildrakizumab for treating moderate to severe plaque psoriasis
Single Technology Appraisal (STA) Tildrakizumab for treating moderate to severe plaque psoriasis Response to consultee and commentator comments on the draft remit and draft scope (pre-referral) Please
More informationTechnology appraisal guidance Published: 4 June 2015 nice.org.uk/guidance/ta340
Ustekinumab for treating active psoriatic arthritis Technology appraisal guidance Published: 4 June 2015 nice.org.uk/guidance/ta340 NICE 2017. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationLacosamide (Vimpat) for partial-onset epilepsy monotherapy. December 2011
Lacosamide (Vimpat) for partial-onset epilepsy monotherapy This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a
More informationThey are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:
bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to be used online. They are updated regularly as new NICE guidance is published. To view the latest
More informationAbatacept (Orencia) for active rheumatoid arthritis. August 2009
Abatacept (Orencia) for active rheumatoid arthritis August 2009 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationixekizumab 80mg solution for injection (Taltz ) SMC No. (1223/17) Eli Lilly and Company Ltd.
ixekizumab 80mg solution for injection (Taltz ) SMC No. (1223/17) Eli Lilly and Company Ltd. 10 March 2017 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and
More informationCertolizumab pegol (Cimzia) for the treatment of ankylosing spondylitis second or third line
Certolizumab pegol (Cimzia) for the treatment of ankylosing spondylitis second or third line August 2011 This technology summary is based on information available at the time of research and a limited
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 13 May 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 13 May 2009 STELARA 45 mg, solution for injection B/1 x 0.5 ml vial (CIP code: 392 586-2) JANSSEN-CILAG Ustekinumab
More informationInfliximab (Remicade) for paediatric ulcerative colitis - second line
Infliximab (Remicade) for paediatric ulcerative colitis - second line September 2011 This technology summary is based on information available at the time of research and a limited literature search. It
More informationHorizon Scanning Technology Summary. Adalimumab (Humira) for juvenile idiopathic arthritis. National Horizon Scanning Centre.
Horizon Scanning Technology Summary National Horizon Scanning Centre Adalimumab (Humira) for juvenile idiopathic arthritis June 2007 This technology summary is based on information available at the time
More informationHorizon Scanning Centre January Apremilast for psoriatic arthritis SUMMARY NIHR HSC ID: 3716
Horizon Scanning Centre January 2013 Apremilast for psoriatic arthritis SUMMARY NIHR HSC ID: 3716 This briefing is based on information available at the time of research and a limited literature search.
More informationUstekinumab for the treatment of moderate to severe psoriasis
DOI: 10.3310/hta13suppl3/10 Health Technology Assessment 2009; Vol. 13: Suppl. 3 Ustekinumab for the treatment of moderate to severe psoriasis E Gospodarevskaya, J Picot, K Cooper, E Loveman* and A Takeda
More informationUSTEKINUMAB. London New Drugs Group APC/DTC Briefing Document. May 2009
Page 1 London New Drugs Group APC/DTC Briefing Document USTEKINUMAB Contents Summary 1 Background 4 Clinical efficacy 5 Cost implications 9 Reference list 10 Appendices 11 Produced for the London New Drugs
More informationTechnology appraisal guidance Published: 25 November 2015 nice.org.uk/guidance/ta368
Apremilast for treating moderate to severe ere plaque psoriasis Technology appraisal guidance Published: 25 November 2015 nice.org.uk/guidance/ta368 NICE 2015. All rights reserved. Contents 1 Guidance...
More informationHorizon Scanning Centre November Vinflunine (Javlor) monotherapy for advanced breast cancer SUMMARY NIHR HSC ID: 7887
Horizon Scanning Centre November 2012 Vinflunine (Javlor) monotherapy for advanced breast cancer SUMMARY NIHR HSC ID: 7887 This briefing is based on information available at the time of research and a
More informationFinal Appraisal Report. Etanercept (Enbrel. Pfizer Limited. Advice No: 0210 March Recommendation of AWMSG
Final Appraisal Report Etanercept (Enbrel ) Pfizer Limited Advice No: 0210 March 2010 Recommendation of AWMSG Etanercept (Enbrel ) is not recommended for use within NHS Wales for the treatment of chronic
More informationTechnology appraisal guidance Published: 12 July 2017 nice.org.uk/guidance/ta455
Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people Technology appraisal guidance Published: 12 July 2017 nice.org.uk/guidance/ta455 NICE 2017. All rights
More informationLiraglutide (Victoza) in combination with basal insulin for type 2 diabetes
Liraglutide (Victoza) in combination with basal insulin for type 2 diabetes May 2011 This technology summary is based on information available at the time of research and a limited literature search. It
More informationHorizon Scanning Technology Summary. Abatacept (Orencia) for juvenile idiopathic arthritis. National Horizon Scanning Centre.
Horizon Scanning Technology Summary National Horizon Scanning Centre Abatacept (Orencia) for juvenile idiopathic arthritis June 2007 This technology summary is based on information available at the time
More informationHorizon Scanning Centre November Enobosarm (Ostarine) for cachexia in patients with advanced non-small cell lung cancer first line
Horizon Scanning Centre November 2012 Enobosarm (Ostarine) for cachexia in patients with advanced non-small cell lung cancer first line SUMMARY NIHR HSC ID: 5206 This briefing is based on information available
More informationCilengitide (Impetreve) for glioblastoma multiforme. February 2012
Cilengitide (Impetreve) for glioblastoma multiforme February 2012 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationKEY MESSAGES. Psoriasis patients are more prone to cardiovascular diseases, stroke, lymphoma and non-melanoma skin cancers, and increased mortality.
KEY MESSAGES Psoriasis is a genetically determined, systemic immune-mediated chronic inflammatory disease that affects primarily the skin and joints. Psoriasis Vulgaris is characterised by well-demarcated
More informationBotulinum toxin A (Dysport) for hyperhidrosis of the axillae
April 2016 Horizon Scanning Research & Intelligence Centre Botulinum toxin A (Dysport) for hyperhidrosis of the axillae LAY SUMMARY This briefing is based on information available at the time of research
More informationTechnology appraisal guidance Published: 26 April 2017 nice.org.uk/guidance/ta442
Ixekizumab for treating moderate to severe ere plaque psoriasis Technology appraisal guidance Published: 26 April 2017 nice.org.uk/guidance/ta442 NICE 2017. All rights reserved. Subject to Notice of rights
More informationHorizon Scanning Centre November Spheroids of human autologous matrix-associated chondrocytes (Chondrosphere) for articular cartilage defects
Horizon Scanning Centre November 2014 Spheroids of human autologous matrix-associated chondrocytes (Chondrosphere) for articular cartilage defects SUMMARY NIHR HSC ID: 8515 This briefing is based on information
More informationCADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION
CADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION IXEKIZUMAB (Taltz Eli Lilly Canada Inc.) Indication: Moderate to Severe Plaque Psoriasis Recommendation: The CADTH Canadian Drug Expert Committee
More informationustekinumab (Stelara )
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationIxekizumab for treating moderate to severe plaque psoriasis [ID904]
Thank you for agreeing to make a submission on your organisation s view of the technology and the way it should be used in the NHS. Healthcare professionals can provide a unique perspective on the technology
More informationInsulin degludec/insulin aspart (DegludecPlus) for type 1 diabetes
Insulin degludec/insulin aspart (DegludecPlus) for type 1 diabetes This technology summary is based on information available at the time of research and a limited literature search. It is not intended
More informationApixaban for stroke prevention in atrial fibrillation. August 2010
Apixaban for stroke prevention in atrial fibrillation August 2010 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationOlesoxime for amyotrophic lateral sclerosis first line
Olesoxime for amyotrophic lateral sclerosis first line May 2011 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Proposed Single Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Proposed Single Technology Appraisal Apremilast for treating moderate to severe plaque psoriasis ID679 Consultee and commentator comment form Please use
More informationEtanercept: a new option in paediatric plaque psoriasis
: a new option in paediatric plaque psoriasis Steve Chaplin MSc, MRPharmS, Medical Writer, Dr David Atherton MA, MB, BChir, FRCP, Honorary Consultant in Paediatric Dermatology, Great Ormond Street Hospital
More informationTRANSPARENCY COMMITTEE OPINION. 26 April 2006
TRANSPARENCY COMMITTEE OPINION 26 April 2006 REMICADE 100 mg powder for concentrate for solution for infusion Box of 1 (CIP code: 562 070.1) Applicant : laboratoires Schering Plough List I Drug for hospital
More informationPsoriasis. Dr. Pablo de la Cueva Hospital Universitario Infanta Leonor Madrid
Psoriasis Dr. Pablo de la Cueva Hospital Universitario Infanta Leonor Madrid PSORIASIS Psoriasis News. Topical treatment Calcipotriene/Betamethasone Dipropionate (Cal/BD) foam: In the real-world, Cal/BD
More informationRoflumilast (Daxas) for chronic obstructive pulmonary disease
Roflumilast (Daxas) for chronic obstructive pulmonary disease August 2009 This technology summary is based on information available at the time of research and a limited literature search. It is not intended
More informationThe Cosentyx clinical trial programme 1-11
The Cosentyx clinical trial programme 1-11 There are eight pivotal trials (four in psoriasis, two in psoriatic arthritis, two in ankylosing spondylitis) There are two head-to-head trials in psoriasis showing
More informationBrodalumab for treating moderate to severe plaque psoriasis [ID878]
Brodalumab for treating moderate to severe plaque psoriasis [ID878] Thank you for agreeing to give us your organisation s views on this technology and its possible use in the NHS. You can provide a unique
More informationPsoriasis management. A/Prof Amanda Oakley Dermatologist, Waikato
Psoriasis management A/Prof Amanda Oakley Dermatologist, Waikato AbbVie Breakfast Session, 14 June 2014 Disclosure This breakfast session is sponsored by Abbvie Autoimmune skin disorders Psoriasis Eczema
More informationClinical Policy: Ustekinumab (Stelara) Reference Number: ERX.SPMN.167
Clinical Policy: (Stelara) Reference Number: ERX.SPMN.167 Effective Date: 10/16 Last Review Date: 12/16 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationHorizon Scanning Centre November 2012
Horizon Scanning Centre November 2012 Cangrelor to reduce platelet aggregation and thrombosis in patients undergoing percutaneous coronary intervention99 SUMMARY NIHR HSC ID: 2424 This briefing is based
More informationHorizon Scanning Centre March Cholic acid (Orphacol) for inborn errors of primary bile acid synthesis first line SUMMARY NIHR HSC ID: 9468
Horizon Scanning Centre March 2014 Cholic acid (Orphacol) for inborn errors of primary bile acid synthesis first line SUMMARY NIHR HSC ID: 9468 This briefing is based on information available at the time
More informationAR101 peanut allergy immunotherapy for adult and paediatric patients
AR101 peanut allergy immunotherapy for adult and paediatric patients NIHRIO (HSRIC) ID: 11815 NIHR Innovation Observatory Evidence Briefing: May 2017 NICE ID: 8773 LAY SUMMARY Food allergy occurs when
More informationKTE-C19 for relapsed or refractory mantle cell lymphoma
NIHR Innovation Observatory Evidence Briefing: July 2017 KTE-C19 for relapsed or refractory mantle cell lymphoma NIHRIO (HSRIC) ID: 11846 NICE ID: 9122 LAY SUMMARY Mantle cell lymphoma is an uncommon type
More informationPasireotide Long-Acting Repeatable (Signifor) for acromegaly first and second line
Pasireotide Long-Acting Repeatable (Signifor) for acromegaly first and second line December 2010 This technology summary is based on information available at the time of research and a limited literature
More informationScottish Medicines Consortium
Scottish Medicines Consortium abatacept, 250mg powder for concentrate for solution (Orencia ) No. (400/07) Bristol Myers Squibb Pharmaceuticals Ltd 10 August 2007 The Scottish Medicines Consortium has
More informationThank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS.
Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS. Healthcare professionals can provide a unique perspective on the technology
More informationA systematic review of treatments for severe psoriasis Griffiths C E, Clark C M, Chalmers R J, Li Wan Po A, Williams H C
A systematic review of treatments for severe psoriasis Griffiths C E, Clark C M, Chalmers R J, Li Wan Po A, Williams H C Authors' objectives To compare the effectiveness of currently available treatments
More informationBackground AN UPDATED LOOK AT TREATMENTS FOR PLAQUE PSORIASIS JULY 2018 PLAQUE PSORIASIS TARGETED IMMUNOMODULATORS AS A TREATMENT OPTION
JULY 2018 Background PLAQUE PSORIASIS Plaque psoriasis is a common disease affecting 3% of the US population that causes itchy, red, scaly, raised lesions on the skin, most commonly on the elbows, knees,
More informationAn otherwise healthy 12-year-old
1105 Photo Rounds.finalREV 10/19/05 2:05 PM Page 947 A young girl with scaly skin plaques The patient had numerous thick red plaques on her back and the extensor surfaces of elbows, knees, and forearms
More informationUSTEKINUMAB Generic Brand HICL GCN Exception/Other USTEKINUMAB STELARA GUIDELINES FOR USE
Generic Brand HICL GCN Exception/Other USTEKINUMAB STELARA 36187 GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) 1. Does the patient have a diagnosis of psoriatic arthritis (PsA)
More informationB-cell lymphoma vaccine (BiovaxID) for follicular non-hodgkin s lymphoma
B-cell lymphoma vaccine (BiovaxID) for follicular non-hodgkin s lymphoma May 2010 This technology summary is based on information available at the time of research and a limited literature search. It is
More informationdimethyl fumarate 30mg and 120mg gastro-resistant tablets (Skilarence ) SMC No 1313/18 Almirall Limited
dimethyl fumarate 30mg and 120mg gastro-resistant tablets (Skilarence ) SMC No 1313/18 Almirall Limited 9 March 2018 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationInsulin glulisine (Apidra) for type 1 diabetes mellitus in adolescents and children
Insulin glulisine (Apidra) for type 1 diabetes mellitus in adolescents and children December 2008 This technology summary is based on information available at the time of research and a limited literature
More informationPediatric Use: Safety and effectiveness of Ustekinumab (STELARA ) in pediatric patients have not been evaluated.
Original Issue Date (Created): January 1, 2010 Most Recent Review Date (Revised): January 28, 2014 Effective Date: April 1, 2014 I. POLICY Preauthorization Requirements for Ustekinumab (STELARA ) Note:
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Otezla (apremilast) Page 1 of 7 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Otezla (apremilast) Prime Therapeutics will review Prior Authorization requests Prior
More informationThe role of current biologic therapies in psoriasis
: An Update on and IL-17 Inhibitors Joanna Dong, BA; Gary Goldenberg, MD PRACTICE POINTS The newest biologics for treatment of moderate to severe plaque psoriasis are and IL-17 inhibitors with unprecedented
More informationDenosumab (AMG 162) for bone metastases from solid tumours and multiple myeloma
Denosumab (AMG 162) for bone metastases from solid tumours and multiple myeloma September 2008 This technology summary is based on information available at the time of research and a limited literature
More informationTicagrelor (Brilique) for peripheral arterial disease
July 2016 Horizon Scanning Research & Intelligence Centre Ticagrelor (Brilique) for peripheral arterial disease LAY SUMMARY This briefing is based on information available at the time of research and a
More informationBilaga 1.till rapport. Bilaga 1 Tabell över inkluderade studier/ Appendix 1 Description of included studies
Bilaga 1.till rapport Ljusbehandling och systemisk behandling av psoriasis, rapport nr 278 (2018) Bilaga 1 Tabell över inkluderade studier/ Appendix 1 Description of included studies Description of included
More informationCabazitaxel (XRP-6258) for hormone refractory, metastatic prostate cancer second line after docetaxel
Cabazitaxel (XRP-6258) for hormone refractory, metastatic prostate cancer second line after docetaxel April 2009 This technology summary is based on information available at the time of research and a
More informationErlotinib (Tarceva) for non small cell lung cancer advanced or metastatic maintenance monotherapy
Erlotinib (Tarceva) for non small cell lung cancer advanced or metastatic maintenance monotherapy September 2008 This technology summary is based on information available at the time of research and a
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Apremilast Table of Contents Coverage Policy... 1 General Background... 2 Coding/Billing Information... 4 References... 4 Effective Date... 1/1/2018 Next
More informationTechnology appraisal guidance Published: 25 August 2010 nice.org.uk/guidance/ta199
Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis Technology appraisal guidance Published: 25 August 2010 nice.org.uk/guidance/ta199 NICE 2018. All rights reserved. Subject
More informationapremilast 10mg, 20mg, 30mg tablets (Otezla ) SMC No. (1053/15) Celgene Ltd.
apremilast 10mg, 20mg, 30mg tablets (Otezla ) SMC No. (1053/15) Celgene Ltd. 08 May 2015 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards
More informationGuselkumab for treating moderate to severe plaque psoriasis [ID1075]
Guselkumab for treating moderate to severe plaque psoriasis [ID1075] Thank you for agreeing to give us your organisation s views on this technology and its possible use in the NHS. You can provide a unique
More informationEtanercept and efalizumab for the treatment of adults with psoriasis. NICE technology appraisal guidance 103. Issue date: July 2006
Issue date: July 2006 Review date: deferred until 2010 Etanercept and efalizumab for the treatment of adults with psoriasis NICE technology appraisal guidance 103 NICE technology appraisal guidance 103
More informationClinical Policy: Ustekinumab (Stelara) Reference Number: CP.PHAR.264
Clinical Policy: (Stelara) Reference Number: CP.PHAR.264 Effective Date: 08/16 Last Review Date: 05/16 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationPsoriasis. Andrei Metelitsa, MD, FRCPC, FAAD Clinical Associate Professor, Dermatology, U of C Co-Director, Institute for Skin Advancement
Psoriasis Andrei Metelitsa, MD, FRCPC, FAAD Clinical Associate Professor, Dermatology, U of C Co-Director, Institute for Skin Advancement Copyright 2017 by Sea Courses Inc. All rights reserved. No part
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Proposed Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Proposed Health Technology Appraisal Secukinumab for treating ankylosing spondylitis after inadequate response to non-steroidal anti-inflammatory drugs
More informationustekinumab 130mg concentrate for solution for infusion and 90mg solution for injection (Stelara ) SMC No. (1250/17) Janssen-Cilag Ltd
ustekinumab 130mg concentrate for solution for infusion and 90mg solution for injection (Stelara ) SMC No. (1250/17) Janssen-Cilag Ltd 09 June 2017 The Scottish Medicines Consortium (SMC) has completed
More information2017 Blue Cross and Blue Shield of Louisiana
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationClinical Trial Report Synopsis
Clinical Trial Report Synopsis A phase 2a, proof of concept trial, testing twice daily application of LEO 124249 ointment 30 mg/g in the treatment of mild to moderate inverse psoriasis Design of trial:
More informationHorizon Scanning Centre July Daclizumab High Yield Process for relapsing forms of multiple sclerosis first or second line
Horizon Scanning Centre July 2014 Daclizumab High Yield Process for relapsing forms of multiple sclerosis first or second line SUMMARY NIHR HSC ID: 2635 This briefing is based on information available
More informationStelara (ustekinumab)
Stelara (ustekinumab) Last Review Date: 03/01/2018 Date of Origin: 02/15/2011 Document Number: MODA-0117 Dates Reviewed: 03/2011, 06/2011, 09/2011, 12/2011, 03/2012, 06/2012, 09/2012, 03/2013, 06/2013,
More informationCabozantinib for medullary thyroid cancer. February 2012
Cabozantinib for medullary thyroid cancer February 2012 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a definitive
More informationrhngf for neurotrophic keratitis first line
September 2015 Horizon Scanning Research & Intelligence Centre rhngf for neurotrophic keratitis first line LAY SUMMARY This briefing is based on information available at the time of research and a limited
More informationHorizon Scanning Technology Summary. Temozolomide (Temodal) for advanced metastatic melanoma. National Horizon Scanning Centre.
Horizon Scanning Technology Summary National Horizon Scanning Centre Temozolomide (Temodal) for advanced metastatic melanoma April 2007 This technology summary is based on information available at the
More informationNational Horizon Scanning Centre. Irbesartan (Aprovel) for heart failure with preserved systolic function. August 2008
Irbesartan (Aprovel) for heart failure with preserved systolic function August 2008 This technology summary is based on information available at the time of research and a limited literature search. It
More informationNational Horizon Scanning Centre. Ipilimumab (MDX-010) for unresectable stage III or IV metastatic melanoma - first or second line treatment
Ipilimumab (MDX-010) for unresectable stage III or IV metastatic melanoma - first or second line treatment April 2008 This technology summary is based on information available at the time of research and
More informationClinical Policy: Ixekizumab (Taltz) Reference Number: ERX.SPA.122 Effective Date:
Clinical Policy: (Taltz) Reference Number: ERX.SPA.122 Effective Date: 10.01.16 Last Review Date: 11.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationNational Horizon Scanning Centre. Aflibercept (VEGF Trap) for advanced chemo-refractory epithelial ovarian cancer. December 2007
Aflibercept (VEGF Trap) for advanced chemo-refractory epithelial ovarian cancer December 2007 This technology summary is based on information available at the time of research and a limited literature
More informationEli Lilly and Company
Eli Lilly and Company Ixekizumab Phase 2 Psoriasis Data Investment Community Discussion April 10, 2012 Safe Harbor Provision This presentation contains forward-looking statements that are based on management's
More informationThe 73rd Annual Meeting of the American Academy of Dermatology, San Francisco ; March 20-24, 2015 Poster ID: 909
The 73rd Annual Meeting of the American Academy of Dermatology, San Francisco ; March 2-24, 215 Poster ID: 99 Clinical Efficacy and Safety of Brodalumab (KHK4827), Anti-Interleukin-17-Receptor A Fully
More informationNational Horizon Scanning Centre. Bevacizumab (Avastin) in combination with non-taxanes for metastatic breast cancer - first line therapy
Bevacizumab (Avastin) in combination with non-taxanes for metastatic breast cancer - first line therapy December 2007 This technology summary is based on information available at the time of research and
More information2.0 Synopsis. Adalimumab R&D/04/118. (For National Authority Use Only) Referring to Part of Dossier: Volume:
2.0 Synopsis Abbott Laboratories Name of Study Drug: Adalimumab Name of Active Ingredient: Adalimumab Title of Study: Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority
More informationJosephine Mauskopf Miny Samuel Doreen McBride Usha G. Mallya Steven R. Feldman
PharmacoEconomics (2014) 32:395 409 DOI 10.1007/s40273-014-0130-5 SYSTEMATIC REVIEW Treatment Sequencing After Failure of the First Biologic in Cost-Effectiveness Models of Psoriasis: A Systematic Review
More information